NSPR

Business Context and Reporting Period

Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: InspireMD is a medical device company specializing in carotid artery disease treatment. Its portfolio includes the CGuard EPS (CE Mark approved, marketed internationally) and CGuard Prime (FDA PMA approved June 2025). In May 2026, the Company initiated a voluntary recall of the CGuard Prime delivery system in the U.S. due to technical success rate issues, though no new patient safety concerns were identified.

Key Financial Metrics

Note: All figures in thousands except per share data. Net Loss per share (Basic/Diluted) for Q2 2026 was $(0.17) vs $(0.26) in Q2 2025.

Material Changes vs. Prior Period

• Revenue Impact from Recall: While YTD revenue increased 56.3% due to U.S. commercial launch, Q2 revenue remained flat year-over-year. This was driven by a $734,000 revenue reduction from credits issued for the CGuard Prime recall, which offset U.S. sales growth.
• Gross Margin Deterioration: Gross margin turned negative (-43.7% in Q2, -1.7% YTD) compared to positive margins in 2025. This was caused by the recall credits and a $612,000 inventory impairment charge associated with the recalled delivery system.
• Operating Expenses: Selling and marketing expenses increased significantly (25.1% QoQ, 50.3% YTD) due to commercial staffing for the U.S. launch. General and administrative expenses decreased due to lower share-based compensation and the absence of prior-year severance costs.
• Liquidity Position: Cash and cash equivalents increased to $15.1 million from $8.9 million at year-end 2025, primarily due to the maturity of $30 million in marketable securities. However, total assets decreased significantly due to the drawdown of marketable securities.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern. Current resources are insufficient to fund operations for the next 12 months without additional financing.
• Nasdaq Compliance: On July 17, 2026, the Company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has 180 days (until Jan 13, 2027) to regain compliance or face delisting.
• Workforce Reduction: Subsequent to June 30, 2026, the Company initiated a workforce reduction of nearly 20%, expecting $9.0 million in annualized savings. Restructuring charges of $0.9M–$1.2M are expected but not yet recorded.
• Regulatory Status: The Company expects to submit a PMA supplement to the FDA in Q4 2026 regarding the CGuard Prime delivery system modifications. Commercialization in the U.S. remains paused until FDA satisfaction is achieved.
• Geopolitical Risk: Operations and manufacturing are located in Israel. While currently unaffected, ongoing regional conflicts pose risks to supply chain continuity and personnel availability.

Investor Verification Checklist

• Capital Raise Timeline: Verify the status of the $75M Equity Distribution Agreement with BTIG and the likelihood of exercising outstanding warrants (exercise price $1.3827 vs. current trading price ~$0.84).
• Recall Resolution: Monitor the timeline for FDA acceptance of the PMA supplement and the resumption of U.S. sales for CGuard Prime.
• Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 bid price requirement for 10 consecutive days before the January 2027 deadline.
• Cost Cutting Execution: Confirm the realization of the projected $9.0 million in annualized savings from the workforce reduction and the impact on R&D timelines.
• Inventory Valuation: Assess the remaining inventory levels and potential for further write-downs related to the recalled delivery system.